KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Common Equity (2018 - 2025)

Historic Common Equity for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $21.6 billion.

  • BioNTech SE's Common Equity rose 290.14% to $21.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 billion, marking a year-over-year increase of 290.14%. This contributed to the annual value of $20.7 billion for FY2024, which is 477.78% down from last year.
  • As of Q3 2025, BioNTech SE's Common Equity stood at $21.6 billion, which was up 290.14% from $20.9 billion recorded in Q2 2025.
  • BioNTech SE's 5-year Common Equity high stood at $21.8 billion for Q4 2023, and its period low was $3.0 billion during Q1 2021.
  • Moreover, its 5-year median value for Common Equity was $20.5 billion (2024), whereas its average is $18.0 billion.
  • As far as peak fluctuations go, BioNTech SE's Common Equity soared by 89588.49% in 2021, and later tumbled by 822.44% in 2025.
  • BioNTech SE's Common Equity (Quarter) stood at $13.6 billion in 2021, then surged by 50.39% to $20.5 billion in 2022, then grew by 6.46% to $21.8 billion in 2023, then fell by 4.78% to $20.7 billion in 2024, then grew by 4.14% to $21.6 billion in 2025.
  • Its Common Equity stands at $21.6 billion for Q3 2025, versus $20.9 billion for Q2 2025 and $19.9 billion for Q1 2025.